Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Avastin QoL Data In First-Line Glioblastoma Muddy Expansion Plans

Mar 03 2014

• By Sue Sutter

Related Content

Patient-Reported Outcomes Tools Should Be Symptom Specific, FDA Says

Nov 11 2013

Avastin Needs Quality Of Life Data In Confirmatory Glioblastoma Trial – Cmte.

Apr 06 2009

Avastin Clinical Benefit Trumps Anti-Tumor Effect In Glioblastoma, ODAC Says

Apr 06 2009

Expanded Colorectal Cancer Claim Moves <em>Avastin</em> Toward Continuous Use

Jan 25 2013

Can Roche Make A Case For <em>Avastin</em> In Brain Cancer Based On Quality Of Life?

Jun 10 2013

<em>Avastin </em>Takes One Step Forward, One Step Back At ASCO

Jun 03 2013

<em>Avastin</em> Loses Its Breast Cancer Claim; FDA’s Hamburg Opts For Withdrawal Over Restrictions

Nov 21 2011

“Not Another <em>Avastin</em>,” FDA Panel Warns Genentech At <em>Perjeta</em> Review

Sep 16 2013

Related Companies

Genentech, Inc.

Roche Holding AG

Additional Topics

United States Clinical Trials Post Market Regulation & Studies BioPharmaceutical

More from United States

More from North America

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window